A2B Adenosine Receptors Prevent Insulin Resistance by Inhibiting Adipose Tissue Inflammation via Maintaining Alternative Macrophage Activation
- Balázs Csóka1⇑,
- Balázs Koscsó1,
- Gábor Törő2,
- Endre Kókai2,
- László Virág2,3,
- Zoltán H. Németh1,4,
- Pál Pacher5,
- Péter Bai2,3 and
- György Haskó1,2⇑
- 1Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ
- 2Department of Medical Chemistry, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
- 3Cell Biology and Signalling Research Group of the Hungarian Academy of Sciences, Debrecen, Hungary
- 4Department of Surgery, Morristown Medical Center, Morristown, NJ
- 5National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
- Corresponding authors: Balázs Csóka, , or György Haskó, .
Obesity causes increased classical and decreased alternative macrophage activation, which in turn cause insulin resistance in target organs. Because A2B adenosine receptors (ARs) are important regulators of macrophage activation, we examined the role of A2B ARs in adipose tissue inflammation and insulin resistance. A2B AR deletion impaired glucose and lipid metabolism in mice fed chow but not a high-fat diet, which was paralleled by dysregulation of the adipokine system, and increased classical macrophage activation and inhibited alternative macrophage activation. The expression of alternative macrophage activation–specific transcriptions factors, including CCAAT/enhancer-binding protein-β, interferon regulatory factor 4, and peroxisome proliferator–activated receptor-γ, was decreased in adipose tissue of A2B AR–deficient mice. Furthermore, in in vitro studies, we found that stimulation of A2B ARs suppressed free fatty acid–induced deleterious inflammatory and metabolic activation of macrophages. Moreover, AR activation upregulated the interleukin-4–induced expression of CCAAT/enhancer-binding protein-β, interferon regulatory factor 4, and peroxisome proliferator–activated receptor-γ in macrophages. Altogether, our results indicate that therapeutic strategies targeting A2B ARs hold promise for preventing adipose tissue inflammation and insulin resistance.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0573/-/DC1.
- Received April 10, 2013.
- Accepted November 1, 2013.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.